426 related articles for article (PubMed ID: 37072630)
1. Diseases associated with prematurity in correlation with N-terminal pro-brain natriuretic peptide levels during the early postnatal life.
Fritz AS; Keller T; Kribs A; Hünseler C
Eur J Pediatr; 2023 Jul; 182(7):3075-3082. PubMed ID: 37072630
[TBL] [Abstract][Full Text] [Related]
2. Reference values for N-terminal Pro-brain natriuretic peptide in premature infants during their first weeks of life.
Fritz AS; Keller T; Kribs A; Hünseler C
Eur J Pediatr; 2021 Apr; 180(4):1193-1201. PubMed ID: 33141298
[TBL] [Abstract][Full Text] [Related]
3. Patent ductus arteriosus, systemic NT-proBNP concentrations and development of bronchopulmonary dysplasia in very preterm infants: retrospective data analysis from a randomized controlled trial.
Potsiurko S; Dobryanskyy D; Sekretar L
BMC Pediatr; 2021 Jun; 21(1):286. PubMed ID: 34147090
[TBL] [Abstract][Full Text] [Related]
4. N-terminal-probrain natriuretic peptide as a biomarker of moderate to severe bronchopulmonary dysplasia in preterm infants: A prospective observational study.
Rodríguez-Blanco S; Oulego-Erroz I; Alonso-Quintela P; Terroba-Seara S; Jiménez-González A; Palau-Benavides M
Pediatr Pulmonol; 2018 Aug; 53(8):1073-1081. PubMed ID: 29790673
[TBL] [Abstract][Full Text] [Related]
5. N-Terminal Pro-B Type Natriuretic Peptide as a Marker of Bronchopulmonary Dysplasia or Death in Very Preterm Neonates: A Cohort Study.
Sellmer A; Hjortdal VE; Bjerre JV; Schmidt MR; McNamara PJ; Bech BH; Henriksen TB
PLoS One; 2015; 10(10):e0140079. PubMed ID: 26452045
[TBL] [Abstract][Full Text] [Related]
6. [Risk factors and short-term prognosis of early pulmonary hypertension in preterm infants].
Wang CH; Chen JJ; Ge JJ; Ma XL; Shi LP
Zhonghua Er Ke Za Zhi; 2022 Jul; 60(7):682-687. PubMed ID: 35768356
[No Abstract] [Full Text] [Related]
7. Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates.
Gokulakrishnan G; Kulkarni M; He S; Leeflang MM; Cabrera AG; Fernandes CJ; Pammi M
Cochrane Database Syst Rev; 2022 Dec; 12(12):CD013129. PubMed ID: 36478359
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus.
Harris SL; More K; Dixon B; Troughton R; Pemberton C; Horwood J; Ellis N; Austin N
Eur J Pediatr; 2018 Apr; 177(4):521-532. PubMed ID: 29352349
[TBL] [Abstract][Full Text] [Related]
9. Patent Ductus Arteriosus and Development of Bronchopulmonary Dysplasia-associated Pulmonary Hypertension.
Gentle SJ; Travers CP; Clark M; Carlo WA; Ambalavanan N
Am J Respir Crit Care Med; 2023 Apr; 207(7):921-928. PubMed ID: 36378949
[No Abstract] [Full Text] [Related]
10. N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants.
Nuntnarumit P; Chongkongkiat P; Khositseth A
Acta Paediatr; 2011 Sep; 100(9):1217-21. PubMed ID: 21457304
[TBL] [Abstract][Full Text] [Related]
11. [Risk factors and prognosis of bronchopulmonary dysplasia associated pulmonary hypertension in preterm infants].
Chen C; Huang P; Lin BC; Chen XY; Zhao J; Sun HY; Yu YL; Chen S; Qiu XM; Yang CZ
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):747-752. PubMed ID: 32872715
[No Abstract] [Full Text] [Related]
12. Natriuretic peptides in bronchopulmonary dysplasia: a systematic review.
Xiong T; Kulkarni M; Gokulakrishnan G; Shivanna B; Pammi M
J Perinatol; 2020 Apr; 40(4):607-615. PubMed ID: 31925319
[TBL] [Abstract][Full Text] [Related]
13. Biochemical Screening for Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia.
Montgomery AM; Bazzy-Asaad A; Asnes JD; Bizzarro MJ; Ehrenkranz RA; Weismann CG
Neonatology; 2016; 109(3):190-4. PubMed ID: 26780635
[TBL] [Abstract][Full Text] [Related]
14. Patent ductus arteriosus and the risk of bronchopulmonary dysplasia-associated pulmonary hypertension.
Nawaytou H; Hills NK; Clyman RI
Pediatr Res; 2023 Aug; 94(2):547-554. PubMed ID: 36804505
[TBL] [Abstract][Full Text] [Related]
15. NTproBNP is a useful early biomarker of bronchopulmonary dysplasia in very low birth weight infants.
Méndez-Abad P; Zafra-Rodríguez P; Lubián-López S; Benavente-Fernández I
Eur J Pediatr; 2019 May; 178(5):755-761. PubMed ID: 30820654
[TBL] [Abstract][Full Text] [Related]
16. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus.
Farombi-Oghuvbu I; Matthews T; Mayne PD; Guerin H; Corcoran JD
Arch Dis Child Fetal Neonatal Ed; 2008 Jul; 93(4):F257-60. PubMed ID: 18218660
[TBL] [Abstract][Full Text] [Related]
17. Active versus restrictive ligation strategy for patent ductus arteriosus - A retrospective two-center study of extremely preterm infants born between 22 + 0 and 25 + 6 weeks of gestational age.
Söderström F; Sindelar R; Olsson KW; Yousef S; Todorova D; Pestalozzi J; Mellander M; Raaijmakers R
Early Hum Dev; 2024 Apr; 191():105976. PubMed ID: 38452632
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of risk factors for bronchopulmonary dysplasia with pulmonary hypertension and construction of a prediction nomogram model].
Dai SZ; Li SS; Zhou MY; Xu Y; Zhang L; Zhang YH; Ye DN; Xu LP; Han SP
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):902-909. PubMed ID: 37803857
[No Abstract] [Full Text] [Related]
19. Role of NT-proBNP in the prediction of moderate to severe Bronchopulmonary Dysplasia in preterm infants.
Khan S; Concina VA; Schneider D; Westgate P; Arriagada S; Bada H
Pediatr Pulmonol; 2020 Feb; 55(2):376-382. PubMed ID: 31869001
[TBL] [Abstract][Full Text] [Related]
20. Early NT-proBNP levels as a screening tool for the detection of hemodynamically significant patent ductus arteriosus during the first week of life in very low birth weight infants.
Rodriguez-Blanco S; Oulego-Erroz I; Gautreaux-Minaya S; Perez-Muñuzuri A; Couce-Pico ML
J Perinatol; 2018 Jul; 38(7):881-888. PubMed ID: 29785059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
